"V体育官网入口" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Randomized Controlled Trial
. 2008 May;1(1):36-43.
doi: 10.1111/j.1752-8062.2008.00026.x.

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

Allison B Goldfine  1 , Robert Silver, Waleed Aldhahi, Dongsheng Cai, Elizabeth Tatro, Jongsoon Lee, Steven E Shoelson
Affiliations
Randomized Controlled Trial

V体育平台登录 - Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

Allison B Goldfine et al. Clin Transl Sci. 2008 May.

Abstract (V体育2025版)

Objectives: Chronic subacute inflammation is implicated in the pathogenesis of insulin resistance and type 2 diabetes. Salicylates were shown years ago to lower glucose and more recently to inhibit NF-kappaB activity. Salsalate, a prodrug form of salicylate, has seen extensive clinical use and has a favorable safety profile VSports手机版. We studied the efficacy of salsalate in reducing glycemia and insulin resistance and potential mechanisms of action to validate NF-kappaB as a potential pharmacologic target in diabetes. .

Methods and results: In open label studies, both high (4. 5 g/d) and standard (3. 0 g/d) doses of salsalate reduced fasting and postchallenge glucose levels after 2 weeks of treatment. Salsalate increased glucose utilization during euglycemic hyperinsulinemic clamps, by approximately 50% and 15% at the high and standard doses, respectively, and insulin clearance was decreased. Dose-limiting tinnitus occurred only at the higher dose. In a third, double-masked, placebo-controlled trial, 1 month of salsalate at maximum tolerable dose (no tinnitus) improved fasting and postchallenge glucose levels. Circulating free fatty acids were reduced and adiponectin increased in all treated subjects. V体育安卓版.

Conclusions: These data demonstrate that salsalate improves in vivo glucose and lipid homeostasis, and support targeting of inflammation and NF-kappaB as a therapeutic approach in type 2 diabetes. V体育ios版.

Keywords: adiponectin; glucose; inflammation; insulin resistance; salicylate; salsalate; type 2 diabetes. VSports最新版本.

PubMed Disclaimer

Figures (V体育官网)

Figure 1
Figure 1
Metabolic parameters in subjects prior to treatment (pre, grey boxes) and after 2‐week treatment with 4.5 g/d (n= 7) or 3.0 g/d (n= 9) salsalate (post, black boxes). Fasting data are displayed for (A) blood glucose (mg/dL × 0.0555 = mmol/L), (B) insulin (pM/6.945 =μU/mL), (C) C‐peptide (nM/0.333 = ng/mL), (D) triglyceride (TG, mg/mL × 0.0113 = mmol/L), (E) total cholesterol (mg/dL × 0.0259 = mmol/L), (F) free fatty acids (FFA, mM), (G) C‐reactive protein (CRP, mg/dL), (H) sCD40L (ng/mL), (I) adiponectin (mg/dL), (J) glycated albumin (%), (K) nitrites (μM), (L) NF‐κB activity (arbitrary units), and (M) energy expenditure (kcal/d). Data represent mean ± SEM; *p < 0.05, **p < 0.005.
Figure 2
Figure 2
Euglycemic‐hyperinsulinemic clamp data are shown for subjects treated for 2 weeks with 4.5 g/d or 3.0 g/d salsalate. (A) Exogenous glucose infusion rates (GIR) and (B) rates of total body glucose utilization (Rd) were determined during clamps before (grey boxes) and after (black boxes) 2‐week treatment with 4.5 g/d or 3.0 g/d salsalate. (C) Rates of oxidative (grey boxes) and nonoxidative glucose metabolism (non‐ox, hatched boxes) are shown before and after 2‐week treatment with 4.5 g/d salsalsate. (D) Insulin clearance rates are shown at baseline (pre, grey boxes) and after 2‐week treatment (post, black boxes) with 4.5 g/d or 3.0 g/d salsalate. (E, F) Insulin levels achieved during the clamps (pM/6.945 =μU/mL) are before (dashed grey lines) or after (solid black lines) 4.5 g/d and 3.0 g/d salsalate, respectively. Data represent mean ± SEM; A, *p= 0.02, **p= 0.002. B, *p < 0.009. C, *p= 0.006. D, **p= 0.01, *p= 0.05. E, ANOVA, p < 0.005. F, ANOVA, p < 0.02.
Figure 3
Figure 3
Intravenous glucose tolerance tests (IVGTT). (A, B) Glucose excursions (mg/dL × 0.0555 = mmol/L) and (C, D) insulin responses (pM/6.945 =μU/mL) during IVGTTs were before (pre, dashed grey lines) or after (post, solid black lines) 2‐week treatment with (A, C) 4.5 g/d or (B, D) 3.0 g/d salsalate. (E) The acute (0–10 minutes) and (F) delayed (10–180 minutes) insulin secretory responses to glucose, calculated as the area under the curve (AUC) C‐peptide, at baseline (pre, grey boxes) and after 2‐week treatment (post, black boxes) with 4.5 g/d or 3.0 g/d salsalate. Data represent mean ± SEM; *p= 0.04.
Figure 4
Figure 4
Metabolic parameters of subjects treated with salsalate at highest tolerated dose. (A, B) Fasting glucose levels (mg/dL × 0.0555 = mmol/L) are at baseline and after 2 or 4 weeks of treatment or placebo; (C) change in fasting glucose values are for the salsalate (Sal) and placebo (Pla) groups at 4 weeks. (D) Glycated hemoglobin (%) is shown at baseline and after 4‐week salsalate (Sal) or placebo (Pla). (E, F) Glucose excursions following a liquid meal are before (pre, dashed grey lines) or after (post, solid black lines) 4‐week salsalate or placebo. (G) Changes in glucose (area under the curve, AUC) following liquid meal for salsalate (Sal) and placebo (Pla). Data represent mean ± SEM. *p < 0.04, **p= 0.002
Figure 5
Figure 5
Metabolic parameters. Responses to the liquid meal for subjects treated with (A, C, E) highest tolerated salsalate dose or (B, D, F) placebo are before (pre, dashed grey lines) or after (post, solid black lines) 4‐week treatment. (G) Adiponectin (mg/dL) levels were determined before and after 4‐week maximum tolerated dose salsalate or placebo, **p= 0.001. Insulin, pm/6.945 =μU/mL; C‐peptide nM/0.333 = ng/mL. Data represent mean ± SEM.
See this image and copyright information in PMC

References

    1. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793–1801. - PMC - PubMed
    1. Tataranni PA, Ortega E. A burning question: does an adipokine‐induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes? Diabetes. 2005; 54(4): 917–927. - PubMed
    1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121): 860–867. - PubMed
    1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352(16): 1685–1695. - PubMed
    1. Hansson GK, Libby P. The immune response in atherosclerosis: a double‐edged sword. Nat Rev Immunol. 2006; 6(7): 508–519. - PubMed (VSports注册入口)

V体育安卓版 - Publication types

MeSH terms

LinkOut - more resources